Mabpharm (HKSE:02181) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 09, 2026)


HKSE:02181 Mabpharm Ltd HKSE:02181
38 GF Score
Price HK$0.40
GF Value HK$1.96
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Mabpharm Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Mabpharm's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HKSE:02181 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Mabpharm's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabpharm Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabpharm's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Mabpharm's Margin of Safety % (DCF Earnings Based) falls into.


HKSE:02181
38GF Score
Mabpharm Ltd HKSE:02181
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabpharm (HKSE:02181) Overvalued in 2026?

Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued. The current stock price of HK$0.40 is trading 79.8% below its estimated GF Value™ of HK$1.96. GuruFocus considers Mabpharm to be Possible Value Trap.

Key valuation signals for HKSE:02181:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: HK$1.96 vs. price of HK$0.40 (79.8% below fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabpharm Business Description

Address Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
38GF Score

Get the complete analysis for HKSE:02181

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.40
Price
HK$1.96
GF Value